

Calcium channel blocker (CCB) amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension

Danneels P, et al. Can J Infect Dis Med Microbiol. 2020 Sep 9; 2020:2093468.

- Patients having severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with comorbidity, such as hypertension suffer more severe infection with elevated mortality.
- This study report that CCBs, a type of antihypertensive drug that is widely used in clinics, inhibited the post-entry replication events of SARS-CoV-2 in vitro.
- A retrospective clinical investigation on hospitalized COVID-19 patients with hypertension as the only comorbidity revealed that the CCB amlodipine besylate therapy was associated with a decreased case fatality rate.

The results from this study suggest that Amlodipine administration to COVID-19 patients with hypertension as the comorbidity might improve the disease outcome.